Switching on the Lights for Real-Time Multimodality Tumor Neuroimaging: The Integrated Positron-Emission Tomography/MR Imaging System

References

1. 1.↵
   1. Beyer T,
   2. Townsend DW,
   3. Brun T,
   4. et al

   . A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369–79

   Abstract/FREE Full Text
2. 2.↵
   1. von Schulthess GK,
   2. Schlemmer HP

   . A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 2009; 36 (suppl 1): S3–9

   CrossRefPubMed
3. 3.↵
   1. Pichler BJ,
   2. Judenhofer MS,
   3. Catana C,
   4. et al

   . Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med 2006; 47: 639–47

   Abstract/FREE Full Text
4. 4.↵
   1. Judenhofer MS,
   2. Wehrl HF,
   3. Newport DF,
   4. et al

   . Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 2008; 14: 459–65

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Catana C,
   2. Procissi D,
   3. Wu Y,
   4. et al

   . Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci U S A 2008; 105: 3705–10

   Abstract/FREE Full Text
6. 6.↵
   1. Schlemmer HP,
   2. Pichler BJ,
   3. Schmand M,
   4. et al

   . Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology 2008; 248: 1028–35

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Zaidi H,
   2. Montandon ML,
   3. Slosman DO

   . Magnetic resonance imaging-guided attenuation and scatter corrections in three-dimensional brain positron emission tomography. Med Phys 2003; 30: 937–48

   CrossRefPubMed
8. 8.↵
   1. Hofmann M,
   2. Steinke F,
   3. Scheel V,
   4. et al

   . MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med 2008; 49: 1875–83

   Abstract/FREE Full Text
9. 9.↵
   1. Zaidi H

   . Is MR-guided attenuation correction a viable option for dual-modality PET/MR imaging? Radiology 2007; 244: 639–42

   CrossRefPubMed
10. 10.↵
    1. Wong TZ,
    2. van der Westhuizen GJ,
    3. Coleman RE

    . Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 2002; 12: 615–26

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Sasajima T,
    2. Miyagawa T,
    3. Oku T,
    4. et al

    . Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging 2004; 31: 1244–56

    PubMedWeb of Science
12. 12.↵
    1. Lang FF,
    2. Gilbert MR

    . Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol 2006; 24: 1236–45

    Abstract/FREE Full Text
13. 13.↵
    1. Milker-Zabel S,
    2. Zabel-du Bois A,
    3. Henze M,
    4. et al

    . Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 2006; 65: 222–27. Epub 2006 Feb 20

    CrossRefPubMed
14. 14.↵
    1. Neff T,
    2. Kiessling F,
    3. Brix G,
    4. et al

    . An optimized workflow for the integration of biological information into radiotherapy planning: experiences with T1w DCE-MRI. Phys Med Biol 2005; 50: 4209–23. Epub 2005 Aug 24

    CrossRefPubMed
15. 15.↵
    1. Bisdas S,
    2. Kirkpatrick M,
    3. Giglio P,
    4. et al

    . Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol 2009; 30: 681–88

    Abstract/FREE Full Text
16. 16.↵
    1. Donahue KM,
    2. Krouwer HG,
    3. Rand SD,
    4. et al

    . Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000; 43: 845–53

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Weisskoff RM,
    2. Zuo CS,
    3. Boxerman JL,
    4. et al

    . Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med 1994; 31: 601–10

    PubMedWeb of Science
18. 18.↵
    1. Koh TS,
    2. Zeman V,
    3. Darko J,
    4. et al

    . The inclusion of capillary distribution in the adiabatic tissue homogeneity model of blood flow. Phys Med Biol 2001; 46: 1519–38

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Ostergaard L,
    2. Smith DF,
    3. Vestergaard-Poulsen P,
    4. et al

    . Absolute cerebral blood flow and blood volume measured by magnetic resonance imaging bolus tracking: comparison with positron emission tomography values. J Cereb Blood Flow Metab 1998; 18: 425–32

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Strauss LG,
    2. Dimitrakopoulou-Strauss A,
    3. Haberkorn U

    . Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics. J Nucl Med 2003; 44: 1933–39

    Abstract/FREE Full Text
21. 21.↵
    1. Tailor DR,
    2. Baumgardner JE,
    3. Regatte RR,
    4. et al

    . Proton MRI of metabolically produced H2 17O using an efficient 17O2 delivery system. Neuroimage 2004; 22: 611–18

    CrossRefPubMed
22. 22.↵
    1. Floeth FW,
    2. Pauleit D,
    3. Wittsack HJ,
    4. et al

    . Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg 2005; 102: 318–27

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Pirotte B,
    2. Goldman S,
    3. Massager N,
    4. et al

    . Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 2004; 101: 476–83

    PubMed
24. 24.↵
    1. Grosu AL,
    2. Weber WA,
    3. Franz M,
    4. et al

    . Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 511–19

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Ricci PE,
    2. Karis JP,
    3. Heiserman JE,
    4. et al

    . Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 1998; 19: 407–13

    Abstract
26. 26.↵
    1. Chao ST,
    2. Suh JH,
    3. Raja S,
    4. et al

    . The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001; 96: 191–97

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Hustinx R,
    2. Pourdehnad M,
    3. Kaschten B,
    4. et al

    . PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 2005; 43: 35–47

    CrossRefPubMed
28. 28.↵
    1. Swanson KR,
    2. Chakraborty G,
    3. Wang CH,
    4. et al

    . Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 2009; 50: 36–44. Epub 2008 Dec 17

    Abstract/FREE Full Text
29. 29.↵
    1. Lehmann P,
    2. Vallee JN,
    3. Saliou G,
    4. et al

    . Dynamic contrast-enhanced T2*-weighted MR imaging: a peritumoral brain oedema study. J Neuroradiol 2009; 36: 88–92. Epub 2008 Dec 2

    CrossRefPubMed
30. 30.↵
    1. Kato T,
    2. Shinoda J,
    3. Nakayama N,
    4. et al

    . Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008; 29: 1176–82

    Abstract/FREE Full Text
31. 31.↵
    1. Sadeghi N,
    2. D'Haene N,
    3. Decaestecker C,
    4. et al

    . Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 2008; 29: 476–82

    Abstract/FREE Full Text
32. 32.↵
    1. Wyss MT,
    2. Spaeth N,
    3. Biollaz G,
    4. et al

    . Uptake of 18F-fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis. J Nucl Med 2007; 48: 608–14

    Abstract/FREE Full Text
33. 33.↵
    1. Jacobs AH,
    2. Thomas A,
    3. Kracht LW,
    4. et al

    . 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005; 46: 1948–58

    Abstract/FREE Full Text
34. 34.↵
    1. Price SJ,
    2. Fryer TD,
    3. Cleij MC,
    4. et al

    . Imaging regional variation of cellular proliferation in gliomas using 3′-deoxy-3′-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study. Clin Radiol 2009; 64: 52–63. Epub 2008 Sep 4

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Chaskis C,
    2. Neyns B,
    3. Michotte A,
    4. et al

    . Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 2009; 72: 423–28. Epub 2009 Jan 15

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Hoehn M,
    2. Himmelreich U,
    3. Kruttwig K,
    4. et al

    . Molecular and cellular MR imaging: potentials and challenges for neurological applications. J Magn Reson Imaging 2008; 27: 941–54

    CrossRefPubMed
37. 37.↵
    1. Miletic H,
    2. Fischer YH,
    3. Giroglou T,
    4. et al

    . Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res 2007; 13: 6761–68

    Abstract/FREE Full Text
38. 38.↵
    1. Hood JD,
    2. Bednarski M,
    3. Frausto R,
    4. et al

    . Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296: 2404–07

    Abstract/FREE Full Text